Embolic stroke – European Clinical Trials Information Network https://clinicaltrials.eu Bridging Patients with Clinical Trials Fri, 12 Jun 2026 10:34:48 +0000 en-US hourly 1 https://wordpress.org/?v=7.0 https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png Embolic stroke – European Clinical Trials Information Network https://clinicaltrials.eu 32 32 Study on Long-Term Anticoagulation with Rivaroxaban vs. Acetylsalicylic Acid for Patients at Risk of Stroke After Atrial Fibrillation Ablation https://clinicaltrials.eu/trial/study-on-long-term-anticoagulation-with-rivaroxaban-vs-acetylsalicylic-acid-for-patients-at-risk-of-stroke-after-atrial-fibrillation-ablation/ Wed, 29 Apr 2026 14:57:37 +0000 https://clinicaltrials.eu/trial/study-on-long-term-anticoagulation-with-rivaroxaban-vs-acetylsalicylic-acid-for-patients-at-risk-of-stroke-after-atrial-fibrillation-ablation/ This clinical trial is focused on patients who have undergone a procedure called catheter ablation to treat atrial fibrillation, a condition that can increase the risk of having a stroke. The study is investigating two different treatments to see which is more effective in reducing the risk of stroke and other related events. The first treatment involves the use of a medication called rivaroxaban, which is a type of blood thinner that helps prevent blood clots. The second treatment uses acetylsalicylic acid, commonly known as aspirin, which is also used to prevent blood clots but works in a different way.

The purpose of the study is to determine whether continuing long-term treatment with rivaroxaban is better than using acetylsalicylic acid alone in preventing strokes and other similar events in patients who are at moderate risk after their successful catheter ablation. Participants in the study will be randomly assigned to receive either rivaroxaban or acetylsalicylic acid. Some participants may receive a placebo, which looks like the real medication but does not contain any active ingredients. The study will last for up to 36 months, during which time participants will have regular check-ups and tests to monitor their health and the effects of the treatment.

The main goal is to see if there is a difference in the occurrence of strokes or other related events between the two treatment groups. The study will also look at other outcomes, such as the occurrence of bleeding, changes in brain scans using MRI, and overall quality of life. This information will help doctors understand the best way to prevent strokes in patients who have had atrial fibrillation and have undergone catheter ablation.

]]> Study on Colchicine for Reducing Inflammation in Patients with Stroke or TIA and Atherosclerosis https://clinicaltrials.eu/trial/study-on-colchicine-for-reducing-inflammation-in-patients-with-stroke-or-tia-and-atherosclerosis/ Wed, 29 Apr 2026 14:56:56 +0000 https://clinicaltrials.eu/trial/study-on-colchicine-for-reducing-inflammation-in-patients-with-stroke-or-tia-and-atherosclerosis/ This clinical trial is focused on studying the effects of the medication Colchicine on patients who have experienced a stroke or a transient ischemic attack (TIA), which is often referred to as a “mini-stroke.” The study aims to understand if Colchicine, known for its anti-inflammatory properties, can help reduce certain markers in the blood that indicate inflammation. Inflammation in the blood vessels can increase the risk of having another stroke or heart-related issues, so reducing these markers might lower that risk.

Participants in the study will take Colchicine Tiofarma 500 microgram Tablets once daily for 30 days. The study will involve taking blood samples before and after the treatment to measure changes in inflammation markers. These markers include substances like hsCRP and IL-6, which are proteins in the blood that can indicate inflammation levels. The main goal is to see if there is a significant change in these markers after taking the medication.

The study will also look at how many participants have their hsCRP levels reduced to below a certain level by the end of the treatment. Additionally, it will monitor any side effects or reasons why participants might stop taking Colchicine. This research is important because it could provide new insights into how to prevent further strokes or heart problems in people with a history of these conditions.

]]>